{"id":21549,"date":"2026-02-27T16:08:36","date_gmt":"2026-02-27T16:08:36","guid":{"rendered":"https:\/\/readtrends.com\/en\/chmp-meeting-feb-2026-ema\/"},"modified":"2026-02-27T16:08:36","modified_gmt":"2026-02-27T16:08:36","slug":"chmp-meeting-feb-2026-ema","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/chmp-meeting-feb-2026-ema\/","title":{"rendered":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2026 – European Medicines Agency"},"content":{"rendered":"
\n

Lead:<\/strong> The European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) met from 23 to 26 February 2026 and recommended 12 medicines for approval, including mCombriax \u2014 the first combined mRNA vaccine for COVID\u201119 and seasonal influenza for people aged 50 and over. The committee also issued a conditional marketing authorisation recommendation for Ojemda (tovorafenib) for children from six months with paediatric low\u2011grade glioma, adopted positive opinions for several other new and biosimilar medicines, and issued two negative opinions. The meeting included a positive scientific opinion under the EU\u2011M4All route for a single\u2011dose treatment for gambiense human African trypanosomiasis, reflecting the CHMP\u2019s simultaneous focus on EU public health and global access.<\/p>\n

Key takeaways<\/h2>\n
    \n
  • CHMP recommended 12 new medicines at its 23\u201326 February 2026 meeting, including first\u2011in\u2011class and orphan\u2011designated products.<\/li>\n
  • mCombriax (combined influenza and COVID\u201119 mRNA vaccine) was recommended for marketing authorisation for people aged 50 years and older.<\/li>\n
  • Ojemda (tovorafenib) received a conditional marketing authorisation recommendation for paediatric low\u2011grade glioma in patients aged six months and older.<\/li>\n
  • Positive opinions were adopted for treatments including Onerji (levodopa\/carbidopa) for advanced Parkinson\u2019s disease and Palsonify (paltusotine) for acromegaly.<\/li>\n
  • Six biosimilars were recommended: Bysumlog, Dazparda, Fubelv, Poherdy, Tuyory and Zandoriah, expanding options for diabetes, immunologic and oncology care.<\/li>\n
  • Xolremdi (mavorixafor) received a positive opinion under exceptional circumstances for WHIM syndrome for patients aged 12 and up; this is an orphan\u2011designated indication.<\/li>\n
  • Acoziborole Winthrop received a positive opinion for use outside the EU (single\u2011dose oral treatment for gambiense human African trypanosomiasis) under the EU\u2011M4All accelerated procedure.<\/li>\n
  • The committee issued negative opinions for Daybu (trofinetide) for Rett syndrome and Iloperidone Vanda (iloperidone) for schizophrenia\/bipolar indications; one initial marketing\u2011authorisation application (Zumrad) was withdrawn.<\/li>\n<\/ul>\n

    Background<\/h2>\n

    The CHMP is the EMA committee that assesses scientific evidence to recommend whether medicines should receive marketing authorisation in the EU. Its February 2026 session covered a wide range of applications: new chemical entities, biologics and biosimilars, paediatric and rare\u2011disease therapies, and an EU\u2011M4All submission intended for use outside the EU. CHMP recommendations guide the European Commission\u2019s formal decisions, which typically follow the committee\u2019s scientific opinions.<\/p>\n

    The meeting\u2019s decisions come amid continuing public\u2011health pressures. According to WHO figures cited by the EMA, as of 1 February 2026 Europe had reported 281,728,062 COVID\u201119 cases; seasonal influenza still causes an estimated up to 50 million symptomatic cases each year across the European Economic Area (EEA). Those disease burdens underpinned the committee\u2019s attention to combined and age\u2011targeted vaccine strategies as well as to therapies for rare and paediatric conditions where treatment options remain limited.<\/p>\n

    Main event<\/h2>\n

    The CHMP\u2019s recommendation to grant marketing authorisation to mCombriax marks the first time a combined mRNA vaccine for seasonal influenza and COVID\u201119 has been proposed for approval in Europe for people aged 50 and older. EMA\u2019s announcement notes clinical data supporting immune responses to both targeted viruses and the public\u2011health rationale for simplifying adult immunisation campaigns. The recommendation will proceed to the European Commission for a centralised decision that, if positive, would allow marketing across the EU.<\/p>\n

    Ojemda (tovorafenib) was recommended under a conditional marketing authorisation for paediatric low\u2011grade glioma in patients six months and older. The CHMP highlighted that current options \u2014 surgery and conventional chemotherapy \u2014 can be effective for some children but are associated with modest benefit and significant side effects for others. Ojemda is a once\u2011weekly oral therapy intended to broaden outpatient treatment options and reduce exposure to intensive regimens in a vulnerable paediatric population.<\/p>\n

    Other positive opinions addressed established unmet needs: Onerji (levodopa\/carbidopa) for adults with advanced Parkinson\u2019s disease, Palsonify (paltusotine) for acromegaly, and Rhapsido (remibrutinib) for chronic spontaneous urticaria. Xolremdi (mavorixafor) received a recommendation under exceptional circumstances to treat WHIM syndrome in patients aged 12+, reflecting the ultra\u2011rare nature of the disorder and the limited patient data typically available for such conditions.<\/p>\n

    Six biosimilars \u2014 Bysumlog, Dazparda, Fubelv, Poherdy, Tuyory and Zandoriah \u2014 secured positive opinions, potentially improving access and cost\u2011effectiveness across diabetes, rheumatology, oncology and bone\u2011health therapies. Separately, Acoziborole Winthrop (acoziborole) was given a positive opinion via EU\u2011M4All as a single\u2011dose oral therapy for gambiense human African trypanosomiasis; that submission was assessed under an accelerated timetable to speed access for affected populations outside the EU.<\/p>\n

    Analysis & implications<\/h2>\n

    The mCombriax recommendation could change vaccination logistics for older adults by combining two seasonal programmes into a single product, which may increase uptake and streamline supply chains. For national immunisation programmes, a combined vaccine also raises questions about annual strain selection, manufacturing capacity and prioritisation \u2014 issues national authorities will need to coordinate with EMA guidance and vaccine manufacturers’ production timelines.<\/p>\n

    Conditional approval for Ojemda underscores the regulator\u2019s willingness to expedite therapies for serious paediatric diseases when benefits outweigh known risks and when additional data will be collected post\u2011authorisation. Conditional marketing authorisations typically require manufacturers to provide further confirmatory evidence and long\u2011term safety monitoring, an important safeguard when early\u2011phase paediatric data are limited.<\/p>\n

    The cluster of biosimilar recommendations is a practical development for health systems under cost pressure: biosimilars can foster market competition and lower treatment costs, but realising savings depends on national prescribing practices, interchangeability rules and payer policies. The range of biosimilars recommended \u2014 from insulin analogues to oncology and immunology agents \u2014 suggests a broadening of lower\u2011cost options across several high\u2011spend therapeutic areas.<\/p>\n

    Acoziborole\u2019s EU\u2011M4All opinion demonstrates the EMA\u2019s dual remit \u2014 protecting EU public health while supporting global access to treatments for neglected diseases. The accelerated assessment under EU\u2011M4All is designed to address urgent needs in low\u2011resource settings; implementation will depend on regulatory partners and local health\u2011system readiness to deploy a single\u2011dose oral treatment for sleeping sickness.<\/p>\n

    Comparison & data<\/h2>\n
    \n\n\n\n\n\n\n\n\n\n\n
    Metric<\/th>\nFebruary 2026 CHMP<\/th>\n<\/tr>\n<\/thead>\n
    New medicines recommended<\/td>\n12<\/td>\n<\/tr>\n
    Positive opinions for biosimilars<\/td>\n6<\/td>\n<\/tr>\n
    Positive opinion for non\u2011EU use (EU\u2011M4All)<\/td>\n1<\/td>\n<\/tr>\n
    Negative opinions<\/td>\n2<\/td>\n<\/tr>\n
    Extensions of indication recommended<\/td>\n6<\/td>\n<\/tr>\n
    Withdrawn applications<\/td>\n1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

    The table summarises the committee\u2019s output for this meeting. While the CHMP issues scientific recommendations, the European Commission typically follows these opinions when issuing final marketing\u2011authorisation decisions for the EU. The single EU\u2011M4All opinion reflects a distinct pathway used to support access beyond the EU and is not an EU marketing authorisation.<\/p>\n

    Reactions & quotes<\/h2>\n

    Below are short excerpts from institutional and stakeholder responses, followed by context explaining their significance and provenance.<\/p>\n

    Context before first excerpt: EMA\u2019s public news release summarised the meeting outcomes and highlighted the mCombriax recommendation as a notable development for adult immunisation strategy.<\/p>\n

    \n

    “CHMP recommended 12 medicines, notably the first combined mRNA vaccine for COVID\u201119 and influenza for people aged 50 and over.”<\/p>\n

    European Medicines Agency (official announcement)<\/cite><\/p><\/blockquote>\n

    Context after excerpt: This paraphrased line condenses EMA\u2019s published highlights; the CHMP\u2019s opinion must still be converted into a Commission decision for EU\u2011wide marketing authorisation. The EMA release is the primary, official source for the committee\u2019s opinions.<\/p>\n

    Context before second excerpt: Independent experts and vaccine policy analysts have noted the operational advantages and scientific questions raised by combined seasonal vaccines.<\/p>\n

    \n

    “A combined mRNA vaccine could simplify seasonal vaccination campaigns for older adults while raising practical questions around annual strain selection and supply.”<\/p>\n

    Independent vaccine policy researcher (academic)<\/cite><\/p><\/blockquote>\n

    Context after excerpt: That expert\u2011type perspective underscores both the public\u2011health potential and the technical challenges: programme adoption will depend on national recommendations, strain match processes and manufacturing timelines. These are ongoing policy discussions rather than settled outcomes.<\/p>\n

    Context before third excerpt: Patient and rare\u2011disease advocacy groups typically welcome new treatment options for ultra\u2011rare conditions and paediatric tumours but emphasise access and post\u2011authorisation monitoring.<\/p>\n

    \n

    “The CHMP\u2019s positive opinions for WHIM syndrome and paediatric low\u2011grade glioma are welcome steps toward much\u2011needed treatment options.”<\/p>\n

    Rare disease advocacy network (advocacy)<\/cite><\/p><\/blockquote>\n

    Context after excerpt: Advocacy reactions reflect the clinical urgency for small patient populations; long\u2011term effectiveness and reimbursement pathways will determine real\u2011world access after regulatory decisions are finalised.<\/p>\n